Clinical trials: Bleeding Diathesis
Hemophilia A
ASC618 Gene Therapy in Hemophilia A Patients
Currently, hemophilia A patients are managed with prophylactic or on-demand replacement therapy with recombinant FVIII or alternative therapeutics.
- Trial name
- NCT04676048
- Testing
- ASC618
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- ASC Therapeutics
Immune Thrombocytopenia, Autoantibodies
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance…
- Conditions
- Immune Thrombocytopenia, Autoantibodies, Evan Syndrome, Connective Tissue Diseases
- Trial name
- NCT04993885
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Covid19
Hamburg Edoxaban for Anticoagulation in COVID-19 Study
Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edoxaban on top of standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate anticoagulation strategy = low-dose low-molecular…
- Trial name
- HERO-19 (NCT04542408)
- Testing
- Anticoagulation Agents (Edoxaban and/or high dose LMWH)
- Where
- 10 sites in Germany
- Volunteers
- 140 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
HIV-1 Infection
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
ACTG A5275 was a prospective, double-blind, randomized, placebo-controlled cross-over design pilot study evaluating the effect of atorvastatin on biomarkers of inflammation, coagulopathy, angiogenesis, and T-lymphocyte activation…
- Trial name
- NCT01351025
- Testing
- atorvastatin
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Purpura, Schoenlein-Henoch, Graft Versus Host Disease
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II.
- Conditions
- Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis
- Trial name
- NCT00006055
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fairview University Medical Center
Blood Coagulation Disorders
Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles
Congenital bleeding disorders characterized by abnormal platelet granules include Gray Platelet syndrome (GPS; defective alpha-granules), Hermansky-Pudlak syndrome (HPS; defective delta-granules), and combined alpha delta-storage…
- Trial name
- NCT00086476
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Von Willebrand Disease
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Description of the long-term evolution of patients with von Willebrand disease and treated with Voncento® and of the hemostatic efficacy in the prevention and the treatment of non-surgical bleeding episodes and prevention of…
- Trial name
- OPALE (NCT04657887)
- Testing
- Voncento®
- Where
- 17 sites in France
- Volunteers
- 135 people
- Sponsor
- CSL Behring
Coagulopathy
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
The purpose of this study is to evaluate the clinical utility of thrombelastography (TEG) to predict and identify trauma patients at increased risk of receiving blood transfusion, develop multiple organ failure and mortality.
- Trial name
- RapidTEG (NCT01228058)
- Testing
- RapidTEG test
- Where
- 3 sites in United States
- Volunteers
- 1,450 people
- Sponsor
- The University of Texas Health Science Center, Houston
Hemophilia A
EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan
The aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer/FS in treatment of patients with…
- Trial name
- NCT00932555
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- Taiwan
- Volunteers
- 82 people
- Sponsor
- Bayer
Acquired Thrombotic Thrombocytopenic Purpura
Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP
The objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a real-world setting, and identify predicting…
- Trial name
- REACT-2020 (NCT04985318)
- Testing
- Cablivi®
- Where
- Germany
- Volunteers
- 350 people
- Sponsor
- University of Cologne
Hemophilia B
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B.
- Trial name
- IX-TEND 4001 (NCT06008938)
- Testing
- HEMGENIX, Factor IX (FIX)
- Where
- 12 sites in United States, Austria and 5 more
- Volunteers
- 500 people
- Sponsor
- CSL Behring
Acquired Thrombotic Thrombocytopenic Purpura
Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura
The lack of ADAMTS13 is the only biological marker that is specific for aTTP diagnosis8 and the assessment of ADAMTS13 is of clinical importance because it is essential for the rapid differential diagnosis between aTTP and other…
- Trial name
- NCT05046717
- Testing
- ADAMTS13 Activity Assays
- Where
- 6 sites in Portugal, Spain
- Volunteers
- 500 people
- Sponsor
- Fundación Española de Hematología y Hemoterapía
Hemophilia A
Intensive Replacement Treatment in Haemophilia Patients With Synovitis
Background: Joint haemorrhage represents the most common type of bleeding episode in persons with hemophilia (PwH). In the absence of an adequate prophylaxis with Factor VIII (for hemophilia A) or FIX (for hemophilia B)…
- Trial name
- NCT04784988
- Testing
- EHL-FVIII, FVIII concentrate
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- Federico II University
Liver Cirrhosis, Hemophilia
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
The goal of this observational study is to learn about the changes in coagulation factor VIII and IX levels in patients undergoing liver transplantation to help guide future management of coagulation factor replacement in…
- Conditions
- Liver Cirrhosis, Hemophilia, Hemophilia A, Hemophilia B
- Trial name
- NCT06014320
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Stanford University
Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other
Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.
- Trial name
- NCT03219723
- Testing
- Vonoprazan, Amoxicillin hydrate, Clarithromycin
- Where
- Japan
- Volunteers
- 560 people
- Sponsor
- Takeda
Purpura, Idiopathic Thrombocytopenic Purpura
All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of All-Trans Retinoic Acid (ATRA) combining with High-dose Dexamethasone for the treatment of adults with…
- Trial name
- NCT01882127
- Testing
- All-Trans Retinoid Acid(ATRA), Dexamethasone
- Where
- China
- Sponsor
- Shandong University
Primary Immune Thrombocytopenia (ITP)
Study of Immune Thrombocytopenia Pathogenesis:
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells.
- Trial name
- PTI PARI (NCT02042560)
- Testing
- Blood samples, Spleen samples
- Where
- 3 sites in France
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
PATIENTS WITH UNEXPLAINED BLEEDING DISORDERS
Innovative Approaches to Identify Causative Genetic Variants in Patients With Unexplained Bleeding Disorders
Creation of an Italian network for unexplained bleeding disorders, using integrated multi-omics approaches to improve diagnosis, optimize patient management, and identify novel therapeutic targets.
- Trial name
- UNEX-EMO 2022 (NCT07870057)
- Where
- Italy
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Reversal of Coagulopathy
An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
The purpose of this study is to evaluate efficacy, safety and tolerance of Beriplex® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by vitamin K antagonists in subjects who require…
- Trial name
- BE1116_3003 (NCT00803101)
- Testing
- Beriplex® P/N (Kcentra), Fresh frozen plasma
- Where
- 30 sites in United States, Belarus and 4 more
- Volunteers
- 176 people
- Sponsor
- CSL Behring
Immune Thrombocytopenia
Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag Treatment
This project was undertaken by Qilu Hospital of Shandong University and other well-known hospitals in China. In order to report the alteration of Different Immune Parameters in ITP Patients Receiving Eltrombopag Treatment.
- Trial name
- NCT01864512
- Where
- China
- Sponsor
- Shandong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.